According to a recent LinkedIn post from HistoSonics, the company is highlighting its presence at the AHPBA meeting in Miami Beach, where it is hosting a lunch symposium on the transition of histotripsy from innovation to implementation. The session, titled “Histotripsy in Practice: Real-World Experience, Evidence, and Future Frontiers,” features surgical oncology and general surgery experts from MD Anderson Cancer Center at Cooper and Vanderbilt University.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post indicates that HistoSonics will also be available on the exhibition floor to discuss its Edison Histotripsy System at booth 32/33, while noting that use of the Edison System outside liver applications is currently limited to clinical investigations. For investors, this visibility among hepatopancreatobiliary specialists may support physician awareness, clinical adoption pathways, and future demand for the platform, although regulatory scope and clinical evidence generation remain key determinants of commercial traction and revenue potential.